692 results on '"Yeung, David T."'
Search Results
102. List of Contributors
103. Strategies to Enhance Medical Countermeasures After the Use of Chemical Warfare Agents on Civilians
104. 309 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
105. 177 - Outcomes of ABO Incompatible Allogeneic Haematopoietic Stem Cell Transplant: A Single-Centre Retrospective Cohort Review
106. In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy
107. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
108. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients
109. A Rodent Model of Sulfur Mustard Hematologic Toxicity for the Efficacy Evaluation of Candidate Medical Countermeasures
110. Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities
111. A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up
112. Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study
113. Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia
114. Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study
115. Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes
116. Ocular Surface – Merging Challenges and Opportunities
117. Considerations in developing medical countermeasures against chemical ocular toxicity
118. Abstracts of Presentations from the 2020 Trans-Agency Scientific Meeting on Developing Medical Countermeasures to Treat the Acute and Chronic Effects of Ocular Chemical Toxicity, 25–26 February, Bethesda, Maryland
119. DUX Hunting—Clinical Features and Diagnostic Challenges Associated with DUX4-Rearranged Leukaemia
120. MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies
121. High‐risk B‐cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse
122. The National Institutes of Health Chemical Countermeasures Research Program ( NIH CCRP ): A collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people
123. Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
124. Supporting Fundamental Chemical Toxicology Research To Inform Medical Countermeasure Developments: The National Institutes of Health Chemical Countermeasures Research Program
125. The CounterACT Research Network: Basic Mechanisms and Practical Applications
126. B‐cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
127. Two novel cases of NUTM1‐rearranged B‐cell acute lymphoblastic leukaemia presenting with high‐risk features.
128. Changes in Circulating Levels of the Traumatic Brain Injury Biomarkers S100B and UCH-L1 in Soman Exposed Sprague Dawley Rats
129. Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase
130. Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates
131. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model
132. National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)—August 6/7, 2019
133. The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
134. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
135. RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML
136. Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia
137. A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib
138. A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia
139. High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen
140. Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
141. Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
142. Compound mutations in CML—imaginary bogeyman or real arch-nemesis?
143. Results of the First Completed Clinical Trial of an iPSC-Derived Product: CYP-001 in Steroid-Resistant Acute GvHD
144. HMGN1plays a significant role in CRLF2driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort
145. A Rodent Model of Sulfur Mustard Hematologic Toxicity for the Efficacy Evaluation of Candidate Medical Countermeasures
146. The NIH Medical Research Program Directed Against Chemical Threats 2017 Report on Research Progress and Future Directions
147. 483 - Allogeneic Haematopoietic Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study
148. 482 - Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study
149. 402 - Comparing the Kinetics of Donor Chimerism Following Myeloablative and Reduced Intensity Conditioning Regimens for Allogenic Haematopoietic Stem Cell Transplant
150. Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.